Answers are grounded in this paper and cite their sources.
Model shows neoadjuvant treatment is cost-effective for resectable lung cancer, suggesting favorable reimbursement from NICE.
Neoadjuvant nivolumab + PDC is a highly cost-effective treatment for nmNSCLC. The findings of this model supported positive reimbursement decisions for neoadjuvant nivolumab + PDC from NICE.
No takes yet. Share an insight, caveat, or question.
Russell et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: